SS-31 (30 mg Vial)

SS-31 Research Overview

SS-30 is studied in educational research settings. Available information discusses different concentration references and general research preparation methods.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied for its interaction with cardiolipin in the inner mitochondrial membrane. Research has explored its role in mitochondrial function, electron transport processes, and cellular energy pathways.Scientific studies have evaluated SS-31 in different preclinical research models, including areas related to cardiovascular research, neurological studies, and age-related cellular research. This educational reference provides general scientific information regarding SS-31 research and available literature.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety information, read SS-31 Peptide: Benefits, Uses, Research, and Scientific Background.

Educational guide for research preparation and daily reference information

Standard / Gradual Approach (3.0 mL = ~10 mg/mL)

Application Information: General research reference. Frequency: Once weekly on a consistent day.

Week	Daily Research Amount	Units (mL)
Weeks 1–2	5 mg (5000 mcg)	50 units (0.50 mL)
Weeks 3–8	10 mg (10,000 mcg)	100 units (1.0 mL)

Frequency: Apply once daily at a consistent time. This 30 mg vial prepared with 3.0 mL provides standard reference amounts within a single measurement device for convenience and accuracy.

Preparation Steps

Advanced / Aggressive Approach (3.0 mL = ~10 mg/mL)

Week	Daily Research Amount	Units (mL)
Weeks 1–2	5 mg (5000 mcg)	50 units (0.50 mL)
Weeks 3–4	10 mg (10,000 mcg)	100 units (1.0 mL)
Weeks 5–8	15 mg (15,000 mcg)	Split: 2 × 75 units (0.75 mL each)
Optional Weeks 9–12	20 mg (20,000 mcg)	Split: 2 × 100 units (1.0 mL each)

Note: Advanced research information (15–20 mg/day) is based on short-term scientific references related to mitochondrial research areas and should only be considered with appropriate professional oversight. Amounts above 10 mg may require separate application areas for research handling. Current scientific information has not extensively evaluated SS-31 beyond 12 weeks; extended research use requires careful monitoring.

Important: This guide is for educational purposes only and is not intended as medical guidance.

Plan based on an 8–12 week daily research schedule using 30 mg vials.

Goal: Support understanding of mitochondrial function, ATP production, and oxidative stress research areas.
Schedule: Daily research reference information for 8–12 weeks based on available scientific resources.
Reference Range: 5–10 mg daily (standard reference); 15–20 mg daily (advanced reference under supervision).
Preparation: 3.0 mL per 30 mg vial (~10 mg/mL) for convenient measurement reference.
Storage: Lyophilized material frozen at −20 °C (−4 °F); prepared material refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Suggested daily research approach based on available scientific information.

Start: 5 mg daily for Weeks 1–2 to assess individual response.
Standard Reference: 10 mg daily by Week 3 (commonly referenced amount).
Advanced Reference: 15–20 mg daily for Weeks 5+ (for specific research contexts under supervision).
Frequency: Once per day at a consistent time.
Cycle Length: 8–12 weeks; limited information exists beyond 12 weeks.
Timing: Any consistent time; maintain proper application area rotation.

Proper storage preserves material stability and quality.

Lyophilized: Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for extended periods when frozen.
Prepared: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after preparation; use within 4 weeks for optimal stability.
Avoid Freeze-Thaw: Do not refreeze prepared material; separate portions if needed to minimize temperature changes.

Allow refrigerated vials to reach room temperature before opening to reduce condensation.

Practical considerations for consistency, safety, and general research handling.

Use new sterile syringes for each Research ; dispose in a sharps container.
Application Areas: Rotate areas systematically (abdomen, thighs, upper arms) to maintain consistency and avoid repeated use of the same location.
General Application: Apply materials carefully and follow appropriate handling practices.
Research Observations: Available scientific information discusses temporary local responses that may occur during research handling.
Documentation: Maintain records of research information, dates, and related observations for consistency.
Reference Amounts: For higher research amounts requiring separate applications, maintain appropriate spacing between different areas.

SS-31 (elamipretide) is a cell-permeable tetrapeptide studied for its interaction with mitochondrial structures. Research has explored how this peptide accumulates within the inner mitochondrial membrane and interacts with cardiolipin, a specialized phospholipid involved in cellular energy processes. By influencing cardiolipin-related interactions, SS-31 has been studied in relation to mitochondrial function, electron transport processes, and cellular energy pathways. Scientific research has evaluated SS-31 in different preclinical models, including areas related to cardiovascular research, neurological studies, kidney-related research, and age-associated cellular changes. Available literature continues to explore SS-31 and its potential role in mitochondrial research areas, with ongoing scientific evaluation providing additional understanding over time.

Observations from preclinical models and available scientific references.

Mitochondrial Function: Research has explored SS-31’s interaction with mitochondrial membranes and electron transport processes.
Cellular Energy Pathways: Scientific studies have examined ATP production and reactive oxygen species related to cellular research areas.
Research Models: Studies have evaluated SS-31 in different preclinical research models, including areas related to muscle function and mitochondrial activity.
Scientific Evaluation: Available literature discusses SS-31 in various research fields, including cardiovascular, neurological, and age-related cellular studies.
Laboratory Observations: Research references continue to evaluate different biological markers and cellular processes.

Complementary strategies to support mitochondrial health and optimize general wellness.

Nutrition: Emphasize mitochondrial cofactors including B-vitamins, CoQ10, magnesium, and alpha-lipoic acid; maintain adequate protein intake to support muscle maintenance.
Exercise: Combine resistance training with aerobic activity to support mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.
Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.
Stress Management: Chronic stress can increase oxidative burden; incorporate stress-reduction practices such as meditation, breathwork, or yoga.
Avoid Mitotoxins: Minimize exposure to substances that may affect mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.

General subcutaneous application guidance from available educational resources.

Site Preparation: Clean the vial stopper and application area with alcohol swabs; allow to air-dry completely (30–60 seconds) before proceeding.
Measurement Process: Use a new sterile insulin syringe for each application; measure the required volume from the refrigerated vial; remove any visible air bubbles by gently tapping the syringe.
Application Angle: Pinch a fold of skin (approximately 1–2 inches); insert the needle at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean).
Administration: Apply slowly and steadily over 3–5 seconds; wait 5–10 seconds before withdrawing the needle to minimize leakage.
Site Rotation: Rotate systematically between application areas (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent repeated use and local irritation.
Post-Application: Apply gentle pressure with a clean alcohol swab or cotton ball for a few seconds; do not massage the area vigorously. A small bandage may be applied if needed.
Disposal: Immediately place used syringes in a designated sharps container; never recap needles or dispose of them in regular trash.

This content is intended for educational and research reference purposes only and does not represent medical guidance. SS-31 has been studied in scientific research contexts. Available information regarding specific applications continues to be evaluated through ongoing research. Always consult qualified healthcare professionals before making any health-related decisions. This information is provided for educational purposes only.

International Journal of Molecular Sciences (MDPI)

— Elamipretide: comprehensive review of structure, mechanism of action, and therapeutic potential

British Journal of Pharmacology (PMC)

— Cardiolipin‑binding mechanism and mitochondrial membrane stabilization by SS‑31

U.S. Food & Drug Administration (FDA)

— FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025)

Neurology (AAN Journals

— MMPOWER‑2 trial: elamipretide in primary mitochondrial myopathy

Genetics in Medicine (Nature)

— TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome

Biochimica et Biophysica Acta (BBA) – Bioenergetics

— Cardiolipin remodeling and cristae structure: role in mitochondrial function

Journal of Cardiovascular Pharmacology (PMC)

— SS‑31 reduces oxidative stress and improves mitochondrial bioenergetics

Alzheimer’s Drug Discovery Foundation

— Cognitive Vitality Report: SS‑31 (elamipretide) preclinical and clinical overview

Orphanet Journal of Rare Diseases (PMC)

— Barth syndrome: clinical presentation, diagnosis, and emerging therapies

Centers for Disease Control and Prevention (CDC)

— Vaccine Administration: Educational Reference Information

Johns Hopkins Arthritis Center

— Patient guide: how to give a subcutaneous research (step‑by‑step instructions)

NCBI Bookshelf (StatPearls)

Best Practices for Research Handling: General Preparation and Reference Information

Pharmacologic Considerations of Subcutaneous Drug Administration (PMC)

— Site rotation, absorption kinetics, and prevention of lipohypertrophy